Ken Kato, MD, PhD, National Cancer Center Hospital East
Articles
Applying Data to the Real World in Gastric Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Emerging Approaches in HER2+ Gastric Cancers
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
VEGFR TKIs in Gastroesophageal Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Maintenance Therapy in Gastric Cancers
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Adjuvant Treatment in Gastroesophageal Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Looking Toward the Future in Gastroesophageal Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Toxicity Management in Second Line for Gastric Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Clinical Rationale for Antiangiogenics in Gastric Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Predicting Response With Biomarkers in Gastric Cancers
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Applying New Data in the Real-World for GEJ Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
ESMO 2020: Practice-Changing Data in Esophageal Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
First-Line I/O Successful in Gastric Adenocarcinoma
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Treatment Landscape in Gastric Cancers Pre-ESMO 2020
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Frontline Treatment in Metastatic Gastric Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Optimal Approach Toward Advanced Gastric Cancers in US
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Global Trends in Gastric Cancers
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Latest Updated Articles
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data
